Somatic pharmacogenomics in cancer

被引:21
|
作者
Ikediobi, O. N. [1 ]
机构
[1] Univ Calif San Francisco, Dept Clin Pharm, Sch Pharm, San Francisco, CA 94118 USA
来源
PHARMACOGENOMICS JOURNAL | 2008年 / 8卷 / 05期
关键词
somatic; mutation; cancer; pharmacogenomics; kinase; inhibitor;
D O I
10.1038/tpj.2008.8
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Many of the initial examples of the clinical utility of pharmacogenetics were elucidated in the field of oncology. Those examples were largely based on the existence of germline genetic variation that influences the metabolism of cytotoxic drugs. However, with the development of kinase inhibitors, drugs designed to preferentially target altered proteins driving oncogenesis, pharmacogenetics in cancer has shifted to understanding the somatic differences that determine response to these targeted agents. It is becoming increasingly clear that understanding the molecular genetics of cancer will lead to the further development of targeted therapeutics. Therefore, it is imperative that pharmacogenomics researchers understand the motivations and challenges of developing targeted therapies to treat cancer as a paradigm for personalized medicine. However, much of the discussion in the pharmacogenomics community in cancer is still largely focused on the germline variants as predictors of drug toxicity. In light of that fact, this review presents a detailed discussion of the development of commonly used targeted therapies for the treatment of hematological and solid tumors, the somatic mutations that determine response to those therapies, and the mechanisms of drug resistance.
引用
收藏
页码:305 / 314
页数:10
相关论文
共 50 条
  • [41] Germline pharmacogenomics in the treatment of breast cancer
    Flockhart, D.
    EJC SUPPLEMENTS, 2008, 6 (07): : 55 - 56
  • [42] Cancer pharmacogenomics: Achievements in basic research
    Nakajima M.
    Yokoi T.
    International Journal of Clinical Oncology, 2005, 10 (1) : 14 - 19
  • [43] Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy
    Marsh, Sharon
    Liu, Geoffrey
    ADVANCED DRUG DELIVERY REVIEWS, 2009, 61 (05) : 381 - 387
  • [44] Revisiting the frontiers of pharmacogenomics of colon cancer
    Falandry, Claire
    Bonnefoy, Marc
    Freyer, Gilles
    PHARMACOGENOMICS, 2011, 12 (09) : 1243 - 1244
  • [45] Pharmacogenomics: a tool for improving cancer chemotherapy
    Mariano Monzo
    Alfons Navarro
    Gerardo Ferrer
    Rosa Artells
    Clinical and Translational Oncology, 2008, 10 : 628 - 637
  • [46] The impact of pharmacogenomics on gastrointestinal cancer therapy
    Seufferlein, T
    Boehm, BO
    PHARMACOGENOMICS, 2002, 3 (05) : 625 - 633
  • [47] Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy
    Nishiyama, Masahiko
    Eguchi, Hidetaka
    ADVANCED DRUG DELIVERY REVIEWS, 2009, 61 (05) : 402 - 407
  • [48] UGT pharmacogenomics: implications for cancer risk and cancer therapeutics
    Desai, AA
    Innocenti, F
    Ratain, MJ
    PHARMACOGENETICS, 2003, 13 (08): : 517 - 523
  • [49] Germline Pharmacogenomics in the Treatment of Breast Cancer
    Flockhart, David A.
    DRUG METABOLISM REVIEWS, 2010, 42 : 17 - 18